Committed to the quest

Sometimes, adverse events do not show up until thousands of patients try a new drug. Then they instantly appear on the front page of the newspaper and on the nightly news. Even after studying investigational medical products for years, if not decades, before they reach the market, there is still rea...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical Executive Vol. 21; no. 12; p. 62
Main Author Mayo, Steven W
Format Trade Publication Article
LanguageEnglish
Published Monmouth Junction MultiMedia Healthcare Inc 01.12.2001
Subjects
Altruism
Antihypertensives
Competition
Corporate profits
Headaches
Migraine
Pharmaceutical industry
Product development
R&D
Regulatory approval
Research & development
United States > US
Online AccessGet full text

Cover

More Information
Summary:Sometimes, adverse events do not show up until thousands of patients try a new drug. Then they instantly appear on the front page of the newspaper and on the nightly news. Even after studying investigational medical products for years, if not decades, before they reach the market, there is still really no way to know until it is too late what unfavorable reaction might rear its ugly head. Approval from FDA or other regulatory agencies does not guarantee that a new compound has no adverse effects or even that scientists know everything there is to know about it. It simply means that the drug has been adequately tested across a representative sample of the population and that the product's benefits, according to the best economically feasible statistical sampling methods, outweigh the risks associated with its use.
ISSN:0279-6570
2150-735X